search
Back to results

Evaluation of Polyurethane Male Condoms

Primary Purpose

Contraception, Prevention of Sexually Transmitted Infections

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Sponsored by
Sagami Rubber Industries Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Contraception

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Between the ages of 18 and 45 (inclusive)
  2. Protected against pregnancy by oral contraceptives, an IUD, an implant, contraceptive injections, contraceptive patch, or sterilization (tubal ligation or vasectomy)
  3. Have home internet access, a valid personal email for each partner, ability to videoconference and use electronic signature technology
  4. Willing and able to give electronic informed consent
  5. Willing to respond to questions concerning their reproductive and contraceptive history and use of condoms via interview or self-administered questionnaires
  6. Have vaginal intercourse at least once weekly
  7. Willing to use the study products for fifteen acts of vaginal intercourse within nine weeks of study entry
  8. In a mutually exclusive monogamous relationship with their study partner for at least 6 months and be willing to remain mutually monogamous throughout study participation
  9. Both study partners have previous experience using male condoms
  10. Agree not to use any additional vaginal or sexual lubricant except the AstroglideTM product provided, if desired, supplied by the study
  11. Agree not to expose the study condoms to jewelry (hand, facial, or genital) or piercings (facial or genital) that could damage the study condoms.
  12. Agree not to use sex toys or drugs intended to enhance or diminish sexual response when using study condoms
  13. Male partner agrees to ejaculate during vaginal intercourse
  14. Agree to (or partner) hold the condom at the base of the erect penis during withdrawal
  15. Agree to return any condoms that break during use
  16. Agree to return any unopened condoms
  17. Reachable by telephone

Exclusion Criteria:

  1. Currently participating in another similar clinical study
  2. Female partner self-reported as pregnant
  3. Allergic to natural rubber latex or polyurethane, or has a history of recurrent adverse events following use of latex or polyurethane products
  4. Unable to follow study requirements, use instructions or attend study visits or exchanges
  5. Have a significant (high) risk of STIs, including HIV infection, or having a medical history of recurrent, uncontrolled STIs (e.g. gonorrhoea, syphilis, Chlamydia, etc.)
  6. Currently using condoms for protection against a known STI
  7. Taking any internally applied medication to treat a genital condition that could interact with the study condom
  8. Male partner has used medication that has caused erectile dysfunction, or had difficulty achieving/maintaining an erection, or achieving ejaculation in the last month under typical circumstances/conditions
  9. Male has had a prostatectomy
  10. Any self-reported genitourinary condition (e.g. itching, burning, irritation, etc.) which, in the opinion of the investigator, could affect use of the study condoms or the ability to interpret study data
  11. Employee or affiliate of Essential Access Health or Sagami Rubber Industries Co., Ltd.

Sites / Locations

  • Essential Access Health

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Control Latex Condom C

Polyurethane Condom A

Polyurethane Condom B

Arm Description

Commercial Natural Rubber Latex Male Condom

Polyurethane Condom A (002)

Polyurethane Condom B (001)

Outcomes

Primary Outcome Measures

Non Inferiority Analysis of Each of the Experimental Condoms Verses the Control Condom With Respect to Clinical Failure Rates (Combined Breakage and Slippage) as Per ISO 29943-1:2017.
To confirm each experimental condom is non-inferior to the control condom with respect to total clinical failure rate. The definition of total clinical failure rate as specified in ISO 29943-1:2017 will be used. The Total Clinical Failure Rate is Defined as the Number of Condoms with at least One Acute Failure Event (e.g. Clinical Breakage or Clinical Slippage) Divided by the Number of Condoms Used During Intercourse; Typically Reported as a Percentage; Any Condom which Experiences Multiple Clinical Failure Events Only Count as a Single Clinical Failure. To be eligible for inclusion in the non-inferiority analysis the each couple had to have used at least one of the appropriate experimental condoms and at least one control condom. This means that the numbers of participants and condoms reported in each of the two non-inferiority comparisons will differ.

Secondary Outcome Measures

Full Information

First Posted
November 2, 2020
Last Updated
September 28, 2023
Sponsor
Sagami Rubber Industries Co., Ltd.
Collaborators
Essential Access Health
search

1. Study Identification

Unique Protocol Identification Number
NCT04622306
Brief Title
Evaluation of Polyurethane Male Condoms
Official Title
A Randomized, Masked, 3-way Cross-over, Multi-center, Clinical Investigation to Evaluate Two Polyurethane Condoms in Healthy Monogamous Couples Compared With a Standard Latex Condom
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
October 12, 2020 (Actual)
Primary Completion Date
December 6, 2021 (Actual)
Study Completion Date
December 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sagami Rubber Industries Co., Ltd.
Collaborators
Essential Access Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The clinical study will compare two lubricated polyurethane male condoms of different thickness with a marketed lubricated control male condom made of natural rubber latex. This crossover study will randomize 300 heterosexual couples to the sequence in which they use five condoms of each of the three study condom types. The clinical failure (breakage and slippage) rates of the two polyurethane condoms will be compared to the clinical failure (breakage and slippage) rate of commercial natural rubber latex control condom using a statistical test of non-inferiority. The study will also compare the acceptability of the two polyurethane condom different thickness with that of the natural rubber latex control condom obtained from interviews and questionnaires with subject couples.
Detailed Description
The clinical study will compare two lubricated polyurethane male condoms of different thickness and different sizes with a marketed lubricated control male condom made of natural rubber latex. Couples entering the study will be expected to use 5 of each type of the 3 condoms in a randomised order. The identity of the condoms will be masked to both the couples and the investigators. The aim will be to recruit 300 heterosexual with the intent of achieving a minimum 1,000 uses of each condom type. Couples will report condom use events using a condom report form. The primary information collected will relate to condom breakage and slippage of the penis during use. The total clinical failure rates (breakage and slippage) of the two polyurethane condoms will be compared to the clinical failure (breakage and slippage) rate of commercial natural rubber latex control condom using a statistical test of non-inferiority. The study will also compare the acceptability of the two polyurethane condom different thickness with that of the natural rubber latex control condom obtained from interviews and questionnaires with subject couples.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Contraception, Prevention of Sexually Transmitted Infections

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
300 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control Latex Condom C
Arm Type
Active Comparator
Arm Description
Commercial Natural Rubber Latex Male Condom
Arm Title
Polyurethane Condom A
Arm Type
Experimental
Arm Description
Polyurethane Condom A (002)
Arm Title
Polyurethane Condom B
Arm Type
Experimental
Arm Description
Polyurethane Condom B (001)
Intervention Type
Device
Intervention Name(s)
Control Latex Condom C, Polyurethane Condom A, Polyurethane Condom B
Intervention Description
Condom functionality study to determine failure rates
Primary Outcome Measure Information:
Title
Non Inferiority Analysis of Each of the Experimental Condoms Verses the Control Condom With Respect to Clinical Failure Rates (Combined Breakage and Slippage) as Per ISO 29943-1:2017.
Description
To confirm each experimental condom is non-inferior to the control condom with respect to total clinical failure rate. The definition of total clinical failure rate as specified in ISO 29943-1:2017 will be used. The Total Clinical Failure Rate is Defined as the Number of Condoms with at least One Acute Failure Event (e.g. Clinical Breakage or Clinical Slippage) Divided by the Number of Condoms Used During Intercourse; Typically Reported as a Percentage; Any Condom which Experiences Multiple Clinical Failure Events Only Count as a Single Clinical Failure. To be eligible for inclusion in the non-inferiority analysis the each couple had to have used at least one of the appropriate experimental condoms and at least one control condom. This means that the numbers of participants and condoms reported in each of the two non-inferiority comparisons will differ.
Time Frame
Self Completion of Questionnaires Within 12 Hours of condom use. Questionnaires returned to investigators when receiving next set of 5 condoms. All sets of questionnaires returned within 9 weeks of couple starting.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Between the ages of 18 and 45 (inclusive) Protected against pregnancy by oral contraceptives, an IUD, an implant, contraceptive injections, contraceptive patch, or sterilization (tubal ligation or vasectomy) Have home internet access, a valid personal email for each partner, ability to videoconference and use electronic signature technology Willing and able to give electronic informed consent Willing to respond to questions concerning their reproductive and contraceptive history and use of condoms via interview or self-administered questionnaires Have vaginal intercourse at least once weekly Willing to use the study products for fifteen acts of vaginal intercourse within nine weeks of study entry In a mutually exclusive monogamous relationship with their study partner for at least 6 months and be willing to remain mutually monogamous throughout study participation Both study partners have previous experience using male condoms Agree not to use any additional vaginal or sexual lubricant except the AstroglideTM product provided, if desired, supplied by the study Agree not to expose the study condoms to jewelry (hand, facial, or genital) or piercings (facial or genital) that could damage the study condoms. Agree not to use sex toys or drugs intended to enhance or diminish sexual response when using study condoms Male partner agrees to ejaculate during vaginal intercourse Agree to (or partner) hold the condom at the base of the erect penis during withdrawal Agree to return any condoms that break during use Agree to return any unopened condoms Reachable by telephone Exclusion Criteria: Currently participating in another similar clinical study Female partner self-reported as pregnant Allergic to natural rubber latex or polyurethane, or has a history of recurrent adverse events following use of latex or polyurethane products Unable to follow study requirements, use instructions or attend study visits or exchanges Have a significant (high) risk of STIs, including HIV infection, or having a medical history of recurrent, uncontrolled STIs (e.g. gonorrhoea, syphilis, Chlamydia, etc.) Currently using condoms for protection against a known STI Taking any internally applied medication to treat a genital condition that could interact with the study condom Male partner has used medication that has caused erectile dysfunction, or had difficulty achieving/maintaining an erection, or achieving ejaculation in the last month under typical circumstances/conditions Male has had a prostatectomy Any self-reported genitourinary condition (e.g. itching, burning, irritation, etc.) which, in the opinion of the investigator, could affect use of the study condoms or the ability to interpret study data Employee or affiliate of Essential Access Health or Sagami Rubber Industries Co., Ltd.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Grant R Burt
Organizational Affiliation
Sagami Rubber Industries Co., Ltd.
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
William D Potter, PhD
Organizational Affiliation
Stapleford Scientific Services Limited
Official's Role
Study Director
Facility Information:
Facility Name
Essential Access Health
City
Los Angeles
State/Province
California
ZIP/Postal Code
90010-2648
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Evaluation of Polyurethane Male Condoms

We'll reach out to this number within 24 hrs